Novartis's consumer health unit has decided to recall some of its products in the United States with an aim to serve the consumers in the market with an improved quality standard product.

The reports have confirmed that the Swiss drugmaker has decided to take this $120 million step in the fourth quarter, soon after which it will be voluntarily recalling some of its products for improving their quality standards at its manufacturing sites.

Novartis has also confirmed in a statement of Sunday that to serve their purpose, the company has temporarily put a halt to all the operations as well as shipments at the Novartis Consumer Health (NCH) Lincoln, Nebraska facility. Soon, the company will start accelerating improvements at the site.

"NCH will take a one-time charge currently estimated at $120 million in the fourth quarter of 2011, relating to the recalls and improvement works at the Lincoln facility", Novartis said in the statement.

Novartis has immediately recalled all the lots of select bottle packaging configurations of Excedrin and NoDoz products from its retailers. The recall is for products showing expiry dates of December 20, 2014 or earlier. Also, the list of recalled products includes Bufferin and Gas-X Prevention products having expiry dates of December 20, 2013 or earlier.

The U. S. Food and Drug Administration (FDA) is also well aware of the recall, and fortunately no adverse event has till date been reported regarding any of the batch of the recalled products posting any unhelpful effect for its users, said Novartis.

Novartis has taken the step following the reports of an internal product review that notified about some complaints with issues of broken gelcaps, chipped tablets and inconsistent bottle packaging line clearance practices.